GleamWall
中文EN

IDYA IDEAYA Biosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1676725 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-70.1%
TTM net income YoY-143.0%
TTM EPS YoY-71.4%
Revenue 3-yr CAGR-37.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-4,671.1%
Net margin-3,921.1%
FCF margin-3,592.0%
EBITDA margin-4,637.0%

Returns

ROE-32.7%
ROA-31.0%
ROIC (approx.)-35.9%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets5.8%
Debt / equity0.00x
Current ratio14.97x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-3.0%
Payout ratio—
Capex / revenue55.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$218.71M$7.00M
R&D expense$314.70M$294.67M
SG&A expense$63.32M$39.30M
Operating income-$159.31M-$326.98M
Income tax$0$0
Net income-$113.70M-$274.48M
EBITDA-$156.61M-$324.59M
EPS (basic)-1.28-3.36
EPS (diluted)-1.28-3.36
Weighted avg. shares (diluted)88.49M81.68M
Balance sheet
Cash & equivalents$112.83M$85.18M
Short-term investments$526.56M$591.94M
Receivables—$3,000
Current assets$666.73M$689.71M
PP&E, net$8.22M$8.97M
Total assets$1.11B$1.12B
Current liabilities$58.81M$46.07M
Total liabilities$86.39M$64.94M
Shareholders' equity$1.02B$1.06B
Shares outstanding87.80M86.50M
Cash flow statement
Operating cash flow-$71.10M-$247.58M
Capital expenditure$2.37M$3.86M
Free cash flow-$73.47M-$251.44M
Investing cash flow$69.98M-$502.56M
Financing cash flow$29.78M$677.55M
Depreciation & amortization$2.70M$2.39M
Stock-based compensation$46.12M$34.75M

Free plan shows the latest 2 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.